Pascal Soriot, AstraZeneca CEO (David Zorrakino/Europa Press via AP)

As­traZeneca CEO Pas­cal So­ri­ot aims for 15 new drug launch­es by 2030

As­traZeneca CEO Pas­cal So­ri­ot on Thurs­day un­veiled am­bi­tious plans to launch 15 new drugs by 2030 — and he’s wast­ing no time, with 30 Phase III tri­al ini­ti­a­tions planned this year.

So­ri­ot spies block­buster po­ten­tial in 10 of those pro­grams, he said on the com­pa­ny’s quar­ter­ly earn­ings call, in­clud­ing the com­pa­ny’s oral SERD camizes­trant in ER+/HER2- breast can­cer and Cin­Cor’s bax­dro­stat in hy­per­ten­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.